Last reviewed · How we verify
Duration of DAPT
Duration of DAPT refers to the optimal length of time a patient should remain on dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) following percutaneous coronary intervention.
Duration of DAPT refers to the optimal length of time a patient should remain on dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) following percutaneous coronary intervention. Used for Optimization of dual antiplatelet therapy duration following percutaneous coronary intervention with stent placement.
At a glance
| Generic name | Duration of DAPT |
|---|---|
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
DAPT duration is a clinical management strategy rather than a drug itself, determining how long patients should continue dual antiplatelet therapy to balance the reduction of stent thrombosis and atherosclerotic events against the risk of bleeding complications. The optimal duration varies based on clinical presentation (acute coronary syndrome vs. stable coronary artery disease), stent type (bare-metal vs. drug-eluting), and individual patient bleeding risk. Samsung Medical Center's work in this area likely involves clinical research or guidelines on DAPT duration optimization.
Approved indications
- Optimization of dual antiplatelet therapy duration following percutaneous coronary intervention with stent placement
Common side effects
- Stent thrombosis (if DAPT discontinued prematurely)
- Bleeding complications (if DAPT prolonged)
- Recurrent myocardial infarction
Key clinical trials
- SIMPLAAFY Clinical Trial (NA)
- DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid (NA)
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
- OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina (NA)
- Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2 (NA)
- Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duration of DAPT CI brief — competitive landscape report
- Duration of DAPT updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI